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A role for vitamin D in ovarian cancer etiology is supported by ecologic studies of sunlight exposure, experi-
mental mechanism studies, and some studies of dietary vitamin D intake and genetic polymorphisms in the vitamin
D receptor. However, few studies have examined the association of circulating 25-hydroxyvitamin D (25(OH)D), an
integrated measure of vitamin D status, with ovarian cancer risk. A nested case-control study was conducted
among 7 prospective studies to evaluate the circulating 25(OH)D concentration in relation to epithelial ovarian
cancer risk. Logistic regression models were used to estimate odds ratios and 95% conﬁdence intervals among
516 cases and 770 matched controls. Compared with 25(OH)D concentrations of 50–<75 nmol/L, no statistically
signiﬁcant associations were observed for <37.5 (odds ratio (OR) ¼ 1.21, 95% conﬁdence interval (CI): 0.87, 1.70),
37.5–<50 (OR ¼ 1.03, 95% CI: 0.75, 1.41), or  75 (OR ¼ 1.11, 95% CI: 0.79, 1.55) nmol/L. Analyses stratiﬁed by
tumor subtype, age, body mass index, and other variables were generally null but suggested an inverse associ-
ation between 25(OH)D and ovarian cancer risk among women with a body mass index of  25 kg/m
2 (Pinteraction <
0.01). In conclusion, this large pooled analysis did not support an overall association between circulating 25(OH)D
and ovarian cancer risk, except possibly among overweight women.
case-control studies; cohort studies; ovarian neoplasms; prospective studies; vitamin D
Abbreviations: CI, conﬁdence interval; ICD-O, International Classiﬁcation of Diseases for Oncology; 25(OH)D, 25-hydroxyvitamin
D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; OR, odds ratio; VDPP, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
The pathogenesis of ovarian cancer, one of the most com-
mon gynecologic malignancies, is poorly understood, al-
though hormonal factors, inﬂammation, and wound
healing are thought to play an important role in its etiology
(1). Tubal ligation, parity, and oral contraceptive use are
associated with a reduced risk of ovarian cancer, while post-
menopausal hormone use and a family history of breast and/
or ovarian cancer are associated with an increased risk (2).
Experimental studies suggest that vitamin D may inﬂuence
ovarian carcinogenesis (3–9) through growth inhibition or
induction of apoptosis (3, 7, 10–18). Evidence from eco-
logic studies of ultraviolet B, which initiates vitamin D
production in the skin, and ovarian cancer mortality also
supports a role of vitamin D in ovarian carcinogenesis
(19–23). Results from studies of dietary vitamin D intake
and ovarian cancer risk have been inconsistent but provide
some support for an association (24–28). These studies,
however, were limited as sunlight exposure, the principal
source of vitamin D in humans, often was not considered.
Because blood vitamin D concentrations are inﬂuenced by
both dietary and nondietary factors, they provide an inte-
grated measure of internal vitamin D exposure.
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cases and 603 controls) examined plasma concentrations
of 25-hydroxyvitamin D (25(OH)D) (29), a measure of
overall vitamin D status, and 1,25-dihydroxyvitamin D
(1,25(OH)2D), the most biologically active form of vitamin
D, in relation to ovarian cancer risk. Overall, no statistically
signiﬁcant associations were observed across fourths of
25(OH)D or 1,25(OH)2D and ovarian cancer risk. However,
an inverse association of 25(OH)D with risk was noted
among overweight women (Ptrend ¼ 0.04). Further, having
higher ( 32 ng/mL or approximately  80 nmol/L) versus
lower (<32 ng/mL) 25(OH)D levels had a borderline
inverse association with risk of serous tumors (relative
risk ¼ 0.64, 95% conﬁdence interval (CI): 0.39, 1.05).
Overall, null associations between serum or plasma
25(OH)D and ovarian cancer risk were also observed in 2
other nested case-control studies, which included 201 (30)
and 170 (31) cases of ovarian cancer. However, additional
evidence that vitamin D may play a role in ovarian carcino-
genesis comes from genetic association studies, which have
observed associations between polymorphisms in the vita-
min D receptor (VDR) and ovarian cancer risk (32–34).
Because ovarian cancer is relatively rare, it is necessary to
pool cases and controls from multiple prospective studies to
obtain a large enough sample size to carefully assess the
association between circulating vitamin D concentrations
and risk of ovarian cancer. The association between circu-
latingvitaminDandovariancancerwasexaminedinanested
case-control study combining cases from 7 cohort studies,
with over 500 cases from diverse geographic locations.
MATERIALS AND METHODS
Study design and population
A detailed description of the study design and cohorts
included in the Cohort Consortium Vitamin D Pooling Proj-
ect of Rarer Cancers (VDPP) is provided elsewhere in this
issue (35). Seven cohorts were included in the VDPP ovarian
cancer study: the CLUE Study (CLUE), the Cancer Preven-
tion Study II Nutrition Cohort (CPS-II), the Multiethnic
Cohort Study (MEC), the Nurses’ Health Study, the New
York University Women’s Health Study (NYU-WHS), the
Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial (PLCO), and the Shanghai Women’s Health Study
(SWHS). Cases were female cohort members diagnosed
with primary ovarian cancer (International Classiﬁcation
of Diseases for Oncology (ICD-O) code 56.9) after blood
collection. Analyses were restricted to epithelial ovarian
cases; 14 cases with missing histology were included be-
cause approximately 90% of malignant ovarian tumors are
surface epithelial-stromal tumors (36). With the exception of
the Nurses’ Health Study, histologic subtypes were classiﬁed
as follows: serous (ICD-O codes 8441, 8442, 8460, 8461,
8462);endometrioid(ICD-O codes 8380, 8381,8560, 8570);
mucinous (ICD-O codes 8470, 8471, 8472, 8473, 8480,
8481, 8490); clear cell (ICD-O codes 8310 and 8313); and
otherepithelial (ICD-O codes 8010, 8020, 8050, 8060, 8140,
8260, 8323, 8440, 8450, 9000; missing histology codes).
Histological subtype classiﬁcation in the Nurses’ Health
Study was conducted by a gynecologic pathologist on the
basis of the review of surgical and pathology reports.
Within each cohort, controls were matched to cases by
using the incidence-density method. Controls were selected
from women with at least 1 intact ovary and no history of
cancer (except for nonmelanoma skin cancer or in situ cer-
vical cancer) at the time of case diagnosis and matched in-
dividually to cases at a 1:1 ratio on age at blood collection
(61 year), race/ethnicity (white/black/Asian/other), and
date of blood draw (630 days), with the exception of
Nurses’ Health Study participants who were selected prior
to commencement of the VDPP. In the Nurses’ Health
Study, 3 controls were matched to each case on age (61
year), month of blood collection (61 month), time of day of
blood draw (62 hours), fasting status, menopausal status,
and postmenopausal hormone use at blood draw; although
race/ethnicity was not a matching factor, over 99% of
Nurses’ Health Study participants were white.
Of the initially identiﬁed 546 cases and 808 controls, 30
cases and 38 matched controls were excluded because the
cases were later found to have nonepithelial or mixed ovar-
ian tumors. The ﬁnal analysis included 516 cases and 770
controls, with the number of cases in individual cohorts
ranging from 18 to 127 (Table 1).
Measurement of circulating 25(OH)D
A direct, competitive chemiluminescence immunoassay
using the DiaSorin LIAISON 25 OH Vitamin D TOTAL
Assay (37) was used to measure 25(OH)D in 125 lLo f
serum or plasma. Samples were assayed at Heartland As-
says, Inc., except for Nurses’ Health Study samples, which
had been assayed previously in the laboratory of Dr. Bruce
Hollis using the same method as above (29). Quality control
samples, which comprised 5% of the total sample number
within each cohort set (10% for the Nurses’ Health Study),
came from 2 sources. First, each cohort provided masked
quality control samples for the batch(es) containing its par-
ticipants (more details are provided elsewhere (29, 35)).
Additionally, 2 samples of ‘‘level 1’’ (~60 nmol/L) or ‘‘level
2’’ (~35 nmol/L) vitamin D standard, obtained from the
National Institute of Standards and Technology (NIST),
were included in each batch of 100 samples, except the
Nurses’ Health Study batches. As described by Gallicchio
et al. (35), the intrabatch and interbatch coefﬁcients of var-
iation were 9.3% and 12.7%, respectively, for NIST level 1
samples and 11.0% and 13.6%, respectively, for NIST level
2 samples. For all cohorts except the Nurses’ Health Study,
the median intrabatch coefﬁcient of variation was 9.9%
(range: 3.8%–16.4%), and the median interbatch coefﬁcient
of variation was 13.2% (range: 4.8%–17.0%). For the
Nurses’ Health Study, the intra- and interbatch coefﬁcients
of variation were 6.9% and 9.3%, respectively.
Statistical analyses
Demographic characteristics and major risk factors were
compared between cases and controls using the Wald test,
obtained from conditional logistic regression models that
excluded women with missing data on the characteristic
being compared. Associations between 25(OH)D and
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95% conﬁdence intervals from conditional logistic regres-
sion models (SAS, versions 9.1.3 and 9.2; SAS Institute,
Inc., Cary, North Carolina); all reported P values were 2
sided. Models were adjusted for duration of oral contracep-
tive use and number of pregnancies. Additional adjustment
for other major ovarian cancer risk factors, including family
history of ovarian cancer, postmenopausal hormone use, age
at menarche, age at menopause, body mass index, history of
diabetes, cigarette smoking, alcohol consumption, physical
activity, and education, did not appreciably change the re-
sults. Tubal ligation was not adjusted for in the models
because information for this variable was available only
from a few cohorts. However, tubal ligation is unlikely to
be correlated with circulating 25(OH)D levels and therefore
is unlikely to be a confounder in our study.
Circulating 25(OH)D was classiﬁed into 4 a priori cate-
gories based on clinically relevant cutpoints for the main
analyses: <37.5, 37.5–<50, 50–<75, and  75 nmol/L. The
referent group was 50–<75 nmol/L, because this group in-
cludes the mean level of the US population (62.9160.81
nmol/L for men and 61.5460.85 nmol/L for women), based
on 2000–2004 National Health and Nutrition Examination
Survey data (38). Trend tests were run by using an ordinal
variable assigning the four 25(OH)D groups to values of 1–
4, respectively. Additionally, the ﬁnal models for all cases
and serous tumors were analyzed by using ﬁner vitamin D
categories (<25, 25–<37.5, 37.5–<50, 50–<75, 75–<100,
and  100 nmol/L) for consistency with the VDPP analyses
for other cancer sites.
Analyses alsowere performedbyusing25(OH)Dcategories
constructed according to cohort- and season-speciﬁc quartiles
among controls. In addition, as des c r i b e di nG a l l i c c h i oe ta l .
(35), the residual method was used to carefully adjust for
season, and season-adjusted residual data were then cut into
cohort-speciﬁc quartiles. Results from these analyses were
similar to those using the clinically deﬁned categories and,
therefore, are not presented. To assess the potential inﬂuence
of preclinical disease on the observed association, we per-
formed analyses that excluded the cases that occurred during
either the ﬁrst 2 or 5 years of follow-up.
Stratiﬁed analyses were performed by tumor subtype, age
at blood draw, season of blood draw, race/ethnicity, body
mass index, and oral contraceptive use to evaluate potential
interactions. Odds ratios and 95% conﬁdence intervals were
estimatedbyunconditionallogisticregressionmodels,adjust-
ing for the 4 common matching factors (age, race/ethnicity,
date of blood draw, study cohort), duration of oral contracep-
tive use, and number of pregnancies. The stratiﬁcation vari-
able was included as a covariate in these models, except that
the duration of oral contraceptive use was included as a co-
variate in analyses of ever oral contraceptive users. Interac-
tion tests were conducted by including interaction terms of
the 25(OH)D variable (createdusing the medianvalueamong
controls for each category) with stratiﬁcation level indicator
variables(oneforeachlevel)inthemultiple regressionmodel
(35). The log-likelihood test was used to compare models
with and without the interaction terms.
Ameta-analysisapproachwasusedtocombinedataacross
cohorts (39). Data from the Women’s Health Study (WHS),
which had been included in a prior study with the Nurses’
Health Study (29), were included in the meta-analyses. For
each cohort, the odds ratios and 95% conﬁdence intervals
were estimated for the bottom (<37.5 nmol/L) and top
( 75 nmol/L) 25(OH)D categories compared with the refer-
ence (50–<75 nmol/L) category. Pooled odds ratios and 95%
conﬁdence intervals were obtained using inverse-variance
weighted random-effects models. Heterogeneity across stud-
ies was evaluated. Sensitivity analyses were conducted by
excluding one cohort at a time to evaluate the impact of each
study on the overall results.
RESULTS
The median interval between blood draw and cancer di-
agnosis was 5.9 years, ranging from 2.2 to 10.4 years across
Table 1. Characteristics of Participants, by Cohort, in the Investigation of Ovarian Cancer Within the Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers
Cohort No. of
Cases
No. of
Controls
Time From Blood Collection to
Cancer Diagnosis, median
years (interquartile range)
Circulating 25(OH)D, median nmol/L
(interquartile range)
Cases Controls
CLUE 102 102 9.0 (4.9–13.4) 58.9 (42.7–69.7) 58.4 (45.9–70.4)
CPS-II
a 27 27 2.2 (0.7–3.5) 55.7 (42.9–78.9) 53.9 (42.1–65.3)
MEC 18 18 2.2 (1.3–3.2) 47.6 (31.5–59.0) 48.3 (29.7–60.5)
NHS 127 381 7.3 (3.3–10.6) 65.5 (49.0–79.8) 65.8 (51.3–80.8)
NYU-WHS 94 94 10.4 (5.7–14.9) 48.0 (34.5–62.1) 47.0 (32.8–66.4)
PLCO 74 74 2.6 (1.0–5.1) 53.6 (40.0–73.3) 50.9 (40.9–60.7)
SWHS 74 74 4.3 (2.5–6.3) 36.8 (25.6–48.5) 38.5 (29.5–53.1)
Total 516 770 5.9 (2.7–10.2) 53.2 (38.9–68.7) 57.0 (43.3–72.5)
Abbreviations: CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NHS, Nurses’
Health Study; NYU-WHS, New York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D; PLCO,
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SWHS, Shanghai Women’s Health Study.
a Three CPS-II participants were missing time from blood draw to diagnosis.
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Characteristics
Cases (N 5 516) Controls (N 5 770)
P Value
a
No. %
Median
(Interquartile
Range)
No. %
Median
(Interquartile
Range)
Age at blood draw, years
b 58.0 (50.5–65.0) 57.0 (51.0–64.0) Matched
Season of blood draw Matched
Winter (December–May) 184 35.7 300 39.0
Summer (June–November) 332 64.3 470 61.0
Race Matched
c
White 399 77.3 644 83.6
Black 11 2.1 13 1.7
Asian 82 15.9 83 10.8
Other 12 2.3 11 1.4
Missing 12 2.3 19 2.5
Body mass index, kg/m
2 0.54
<25 248 48.1 400 52.0
25–<30 141 27.3 222 28.8
 30 76 14.7 101 13.1
Missing 51 9.9 47 6.1
Age at menarche, years
b 13 (12–14) 13 (12–14) 0.19
Age at menopause, years
b 49 (44–52) 50 (45–52) 0.01
Ever had full-term pregnancy <0.01
No 62 12.0 51 6.6
Yes 365 70.7 632 82.1
Missing 89 17.2 87 11.3
No. of full-term pregnancies
among parous women
b 2 (2–3) 3 (2–4) <0.001
Ever used oral contraceptive 0.82
No 303 58.7 424 55.1
Yes 157 30.4 275 35.7
Missing 56 10.9 17 9.2
Duration of oral contraceptive
use among oral contraceptive
users, years
b
2.8 (0.5–7.0) 3.0 (1.0–7.5) <0.01
Ever used hormone therapy 0.14
No 133 25.8 148 19.2
Yes 151 29.3 234 30.4
Missing 232 45.0 388 50.4
Smoking status 0.99
Never 296 57.4 408 53.0
Former 147 28.4 248 32.2
Current 65 12.6 92 11.9
Missing 8 1.6 22 2.9
Family history of ovarian cancer <0.001
No 351 68.0 573 74.4
Yes 20 3.9 7 0.9
Missing 145 28.1 190 24.7
Total vitamin D intake, IU/day
b 310.7 (154.2–700.2) 320.2 (171.7–640.3) 0.48
Total calcium intake, mg/day
b 1,004.5 (617.0–1,678.0) 1,074.0 (668.6–1,649.0) 0.91
Total intake of dairy products,
g/day
b 183.8 (66.8–301.4) 219.8 (83.5–369.8) 0.52
a P valueswerederivedfrom theWaldstatistic,generatedbyusingconditionallogisticregressionmodelsamongwomenwithno missingdataon
the characteristic being compared. Cases and controls were matched on age (61 year), race/ethnicity (white, black, Asian, other), date of blood
draw (630 days), and study cohort, except for the Nurses’ Health Study, which was matched on age (61 year), month of blood collection (61
month), time of day of blood draw (62 hours), fasting status, menopausal status, and postmenopausal hormone use at blood draw.
b Median (25th–75th percentiles).
c Nurses’ Health Study participants were not matched on race, although over 99% of included participants were white.
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of circulating 25(OH)D differed considerably across study
cohorts, ranging from 38.5 to 65.8 nmol/L among controls,
with the lowest concentration observed in the Shanghai
Women’s Health Study, the only cohort that included exclu-
sively Asian women. Other cohorts, including primarily Eu-
ropean Americans, generally had a median concentration of
25(OH)D of approximately 50 nmol/L or higher.
Cases and controls were similar in age, race, and season
of blood draw because of the matched study design (Table
2). The median age at blood draw in the study population
was 58 years for cases and 57 for controls. The majority of
study participants were white, and in 64% of cases and 61%
of controls blood samples were obtained during the summer
months. Other characteristics, including education, body
mass index, postmenopausal hormone use, and smoking,
generally were similar between cases and controls. How-
ever, cases were younger at menopause and had fewer
full-term pregnancies compared with controls. Cases also
were slightly less likely to use oral contraceptives and,
among users, had used oral contraceptives for shorter dura-
tions. Additionally, more cases than controls had a family
history of ovarian cancer among ﬁrst-degree relatives.
Overall, there was no statistically signiﬁcant association
betweencirculating 25(OH)D and ovarian cancer risk. Com-
pared with women with 25(OH)D concentrations of 50–<75
nmol/L, the odds ratios were 1.21 (95% CI: 0.87, 1.70)
among women with <37.5 nmol/L, 1.03 (95% CI: 0.75,
1.41) for women with 37.5–<50 nmol/L, and 1.11 (95%
CI: 0.79, 1.55) for women with  75 nmol/L (Ptrend ¼
0.56). Results with expanded cutpoints are shown in Table
3. Results remained similar when each cohort was dropped
in turn from the analysis in sensitivity analyses (data not
shown) and in analyses excluding the ﬁrst 2 or 5 years of
follow-up. Results were unchanged when only serous tu-
mors were included (Ptrend ¼ 0.54). The sample sizes for
endometrioid (n ¼ 50 cases) and mucinous (n ¼ 47 cases)
tumors were too small for reliable analyses.
To evaluate potential heterogeneity in associations, anal-
yses were stratiﬁed by a number of factors, including age at
blood draw, season of blood draw, race/ethnicity, body mass
index, and oral contraceptive use (Table 4). In some in-
stances, there were too few women in a stratum to reliably
evaluate associations (e.g., winter blood draw and non-
whites), and therefore resultsfrom those stratahave notbeen
presented. Overall, ﬁndings were consistent with the main
analyses and did not support a relation between circulating
vitamin D concentrations and ovarian cancer risk. However,
analyses among overweight women suggested an inverse
association between circulating 25(OH)D and ovarian can-
cer risk (Ptrend ¼ 0.01). Among women with a body mass
index  25 kg/m
2, ovarian cancer risk was nonsigniﬁcantly
increased among women with <37.5 nmol/L (odds ratio
(OR) ¼ 1.53, 95% CI: 0.92, 2.55) and nonsigniﬁcantly de-
creased among women with  75 nmol/L (OR ¼ 0.70, 95%
CI: 0.36, 1.35), compared with women whose 25(OH)D
concentrations were between 50 and <75 nmol/L. No sta-
tistically signiﬁcant association, however, was observed
among women with a body mass index below 25. The
interaction test for body mass index and 25(OH)D was
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Am J Epidemiol 2010;172:70–80Table 4. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Ovarian Cancer Risk From Stratiﬁed Analyses in the Cohort Consortium Vitamin
D Pooling Project of Rarer Cancers
Stratiﬁcation Factor
Circulating 25(OH)D, nmol/L
Ptrend
<37.5 37.5–<50 50–<75 ‡75
No. of
Cases
No. of
Controls OR 95% CI No. of
Cases
No. of
Controls OR 95% CI No. of
Cases
No. of
Controls OR 95% CI No. of
Cases
No. of
Controls OR 95% CI
Age at blood draw
<50 years 30 29 18 31 48 62 25 35
Multivariate adjusted
a 0.85 0.40, 1.84 0.52 0.24, 1.09 1.00 Referent 0.91 0.46, 1.80 0.55
 50 years 88 97 95 123 142 258 70 135
Multivariate adjusted
a 1.34 0.91, 1.98 1.20 0.84, 1.71 1.00 Referent 1.15 0.79, 1.68 0.31
Blood draw in summer 60 60 70 83 133 212 69 115
Multivariate adjusted
a 1.25 0.80, 1.97 1.10 0.73, 1.65 1.00 Referent 1.13 0.76, 1.68 0.63
Race/ethnicity, white 62 72 85 124 161 284 91 164
Multivariate adjusted
a 1.18 0.78, 1.79 0.99 0.70, 1.42 1.00 Referent 1.09 0.77, 1.52 0.83
Body mass index
<25 kg/m
2 44 53 42 77 94 162 68 108
Multivariate adjusted
a 1.09 0.63, 1.88 0.72 0.44, 1.18 1.00 Referent 1.21 0.79, 1.86 0.37
 25 kg/m
2 67 64 61 69 72 136 17 54
Multivariate adjusted
a 1.53 0.92, 2.55 1.45 0.90, 2.35 1.00 Referent 0.70 0.36, 1.35 0.01
Oral contraceptive use
Never 81 76 72 88 100 167 50 93
Multivariate adjusted
a 1.40 0.89, 2.20 1.18 0.77, 1.80 1.00 Referent 1.08 0.69, 1.70 0.24
Ever 26 33 28 53 67 121 36 68
Multivariate adjusted
a 1.15 0.59, 2.26 0.71 0.39, 1.28 1.00 Referent 1.01 0.58, 1.75 0.87
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Derived from unconditional logistic regression models adjusting for matching variables (age, race/ethnicity, date of blood draw, and study cohort), duration of oral contraceptive use, and
number of pregnancies. Age at blood draw and season of blood draw were not adjusted for in models stratiﬁed on these variables.
C
i
r
c
u
l
a
t
i
n
g
2
5
(
O
H
)
D
a
n
d
O
v
a
r
i
a
n
C
a
n
c
e
r
R
i
s
k
7
5
A
m
J
E
p
i
d
e
m
i
o
l
2
0
1
0
;
1
7
2
:
7
0
–
8
0statistically signiﬁcant under the multiplicative model
(Pinteraction < 0.01).
In meta-analyses that included data from the Women’s
Health Study and the 7 cohort studies in the VDPP project,
results remained null for overall risk (Figure 1). There was
no evidence of heterogeneity across studies for either the
<37.5 vs. 50–<75 nmol/L or  75 vs. 50–<75 nmol/L anal-
yses (Pheterogeneity ¼ 0.83 and 0.71, respectively), although
individual point estimates did vary, likely in part because of
small sample sizes among some cohorts. Results were sim-
ilar to those from pooled analyses presented in Table 3,
indicating no apparent association between circulating
25(OH)D concentration and ovarian cancer risk.
DISCUSSION
In this large, pooled analysis of 7 prospective cohort stud-
ies, circulating 25(OH)D concentrations were not associated
with ovarian cancer risk overall or in analyses stratiﬁed by
tumor subtype, age at blood draw, or oral contraceptive use.
However, stratiﬁed analyses by body mass index suggested
a possible inverse association between circulating vitamin D
and ovarian cancer risk among overweight and obese
women.
Despite the biologic plausibility, results from this pooled
analysis did not support an association between circulating
25(OH)D and ovarian cancer risk overall. These results are
consistent with those from other studies to date (29–31). In
a pooled analysis of the Nurses’ Health Study, the Nurses’
Health Study II, and the Women’s Health Study by
Tworoger et al. (29), fourths of 25(OH)D or 1,25(OH)2D
were not signiﬁcantly associated with ovarian cancer risk
overall. Both our study and the study byTworoger et al. (29)
included the same Nurses’ Health Study participants (about
25% of the cases in the current study). However, excluding
Nurses’ Health Study cases and controls from our study did
not materially alter the results obtained from all studies
combined. Similarly, overall null associations were ob-
served between serum 25(OH)D and ovarian cancer risk
in a nested case-control study in the Finnish Maternity Co-
hort (30). Serum or plasma 25(OH)D was not associated
with ovarian cancer risk in a case-control study nested
within the New York University Women’s Health Study
and the Northern Sweden Health and Disease Study, nor
was there evidence of an interaction with vitamin D recep-
tor polymorphisms or haplotypes (31). Excluding subjects
(18% of cases in the current pooled analysis) did not alter
the results reported in this paper.
Among women with a body mass index of  25 kg/m
2,
Tworoger et al. (29) observed a signiﬁcant inverse associa-
tion between 25(OH)D quartiles and ovarian cancer risk
(Ptrend ¼ 0.04). A similar inverse association was found in
this study (P ¼ 0.01). In a sensitivity analysis excluding the
Nurses’ Health Study participants, who were also included
in the study by Tworoger et al. (29), our results became
statistically nonsigniﬁcant (Ptrend ¼ 0.16) but the point es-
timates remained similar. Thus, data from these 2 studies
suggest that vitamin D concentrations may be inversely as-
sociated with ovarian cancer risk among overweight and
obese individuals.
Although body mass index is not a clear risk factor for
ovarian cancer (40), some data suggest adiposity is in-
versely associated with circulating 25(OH)D concentra-
tions, likely because vitamin D is fat soluble (41–44). In
rats fed vitamin D supplements, adipose tissue concentra-
tions of vitamin D increased signiﬁcantly; interestingly,
the study reported that vitam i nDw a sr e l e a s e df r o m
adipose tissue, particularly during fasting. This suggests
that adipose tissue may be an important factor in determin-
ing long-term vitamin D status (45). Thus, it is possible
that women with a higher body mass index may have more
bioavailable vitamin D at the tissue level or that circulating
concentrationsmay better reﬂect long-term tissue exposure
in this subpopulation. More research is needed to elucidate
this potential relation.
The median level of 25(OH)D was the lowest among
participants from the Shanghai Women’s Health Study. Ex-
cluding women from this study, however, did not materially
affect the study results. Results stratiﬁed by age at blood
draw and oral contraceptive use suggested no statistically
signiﬁcant interaction of these factors on the association of
circulating vitamin D with ovarian cancer risk. Further, no
associations were observed for speciﬁc histologic subtypes,
although power was limited for some subtype analyses.
Strengths of the current study included a large sample
size, the use of prediagnostic blood samples, and a wide
exposure range due to inclusion of studies in different geo-
graphic locations. Additionally, information was available
on numerous potential demographic and lifestyle factors,
allowing evaluation of potential confounding effects by es-
tablished ovarian cancer risk factors as well as potential
effect modiﬁcation.
One limitation of a pooled analysis is that data were col-
lected using different methods across studies.Because of the
different study methods, harmonization of data was a chal-
lenge, and information on some potential confounders, such
as tubal ligation, was not collected in all studies and there-
fore not included in analyses. However, information was
available on most established risk factors for ovarian cancer,
and it is unlikely that factors such as tubal ligation are
correlated with circulating vitamin D levels.
Even with a relatively largenumber of cases, sample sizes
for some subanalyses were small, such as those stratiﬁed by
tumor subtype and other ovarian cancer risk factors.
Only one blood measurement per person was taken, and
within-person variation in circulating 25(OH)D could have
obscured a true association. However, the correlation over 3
years is around 0.70 for 25(OH)D (46), and unpublished
results from 2 studies in our analysis (New York University
Women’s Health Study and Nurses’ Health Study) showed
high intraclass correlations (35), suggesting that concentra-
tions are relatively stable over time. Additionally, seasonal
variation was addressed in multiple ways, including match-
ing cases and controls on season and constructing cutpoints
based on season-speciﬁc quartiles among controls. Finally,
as with any observational study, it is not possible to com-
pletely eliminate potential confounding effects, although re-
sults were similar in crude and fully adjusted models.
In conclusion, this pooled analysis did not ﬁnd evidence
of a strong overall association between circulating 25(OH)D
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Figure 1. Forest plots for the meta-analysis of the association between circulating 25-hydroxyvitamin D (25(OH)D) and risk of ovarian cancer within the Cohort Consortium Vitamin D Pooling
Project of Rarer Cancers. Risk estimates, by cohort, for subjects with circulating 25(OH)D concentrations <25 nmol/L (A) and  75 nmol/L (B) are compared with the referent group (50–<75 nmol/L).
Odds ratios and 95% conﬁdence intervals were derived from conditional logistic regression models adjusted for duration of oral contraceptive use and number of pregnancies. Cases and controls
w e r em a t c h e do na g e( 61 year), race/ethnicity (white, black, Asian, other), date of blood draw (630 days), and study cohort, except for the Nurses’ Health Study, which was matched on age (61
year), month of blood collection (61 month), time of day of blood draw (62 hours), fasting status, menopausal status, and postmenopausal hormone use at blood draw. The black squares show the
odds ratios, the bars show the 95% conﬁdence intervals, and the size of each square is inversely proportional to the variance of the log odds ratio estimate in each cohort. The overall estimates
(diamonds) come from a meta-analysis using random-effects modeling. CPS-II and SWHS data are not included in the highest versus referent category forest plot (B) because of unstable risk
estimates due to small numbers. CI, conﬁdence interval; CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NHS, Nurses’ Health Study; NYU-WHS, New York
University Women’s Health Study; OR, odds ratio; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SWHS, Shanghai Women’s Health Study; WHS, Women’s Health Study.
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0and ovarian cancer risk. However, there was some sugges-
tion that low circulating vitamin D might be associated with
an increased risk of ovarian cancer among overweight
women.
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